Saturday, April 13News That Matters

Classiq and Quantum Intelligence Corp (QIC, Korea) Partner On Quantum Accelerated Drug Development

Spread the love

–News Direct–

Classiq, a leading quantum computing software company, and Quantum Intelligence Corp. (QIC, Korea) today announced the launch of innovative joint research to accelerate drug development by applying quantum computing to pharmacology. The collaboration is under the auspices of Classiqs Quantum Computing For Life Sciences & Healthcare Center, launched with NVIDIA last year.

This new partnership is dedicated to utilizing the Classiq platform to explore the use of quantum computing in pharmacology for a wide range of predictive and analytical applications. This includes the discovery and design of novel drug candidates as well as the prediction of potential side effects and interactions. The partnership focuses on significantly enhancing the efficiency and accuracy of drug development by integrating Classiq's quantum computing platform with QIC's drug development platform.

Quantum Intelligence diverges from the traditional route of biopharmaceutical companies, positioning itself more as a platform company powered by quantum and AI technology, stated QIC's CEO, Hwanho Choi, MD., PhD. Through this unique collaborative approach, we aim to precisely identify potential side effects early on, reducing risks across all stages of drug development and clinical trials.

QIC, a South Korean startup pioneering the QUEST-ADMET platform based on quantum computing and AI technologies, targets prediction of compound properties through electronic charge distribution algorithms, to efficiently assess therapeutic solution efficacy and safety of drug candidates.

Classiq offers a leading quantum development platform with unique technology enabling high-level abstraction that simplifies and accelerates development of efficient complex quantum software and applications. The Classiq platforms built-in functions, GitHub repository and seamless execution on quantum computing hardware, will be key components in the research to develop pharmacology applications for research.

This agreement marks a significant step towards a new era of accelerated drug development using quantum computing technology, said Classiqs CEO Nir Minerbi. By combining Classiq's quantum computing technology with QIC's drug development platform, we target significant improvements in the efficiency and accuracy of drug development.

About Classiq

Classiq Technologies, the leading quantum software company, provides an all-encompassing platform (IDE, compiler and OS) with a single point of entry into quantum computing, taking users from algorithm design to execution. The high-level descriptive quantum software development environment, tailored to all levels of developer proficiency, automates quantum programming. This ensures that a broad range of talents, including those with backgrounds in AI, ML and linear algebra, can harness quantum computing without requiring deep, specialized knowledge of quantum physics. Classiq democratizes access to quantum computing and equips its users to take full advantage of the quantum computing revolution, including access to a broad range of quantum hardware.

Classiqs core technology, algorithmic quantum circuit compilation, is engineered to power the quantum ecosystem of today and the future. Classiq works closely with quantum cloud providers and advanced computation hardware developers providing software for use with quantum computers, HPC and quantum simulators.

Backed by investors such as HPE, HSBC, Samsung, Intesa Sanpaolo and NTT, Classiqs world-class team of scientists and engineers has distilled decades of quantum expertise into its groundbreaking quantum engine. Follow Classiq on LinkedIn, X (formerly Twitter) or YouTube, and visit the Slack community and website, www.classiq.io to learn more.

About Quantum Intelligence Corp. (QIC)

Founded in 2020 by CEO Dr. Choi Hwanho and CTO Dr. Kang Hong-seok, Quantum Intelligence Corp. (QIC), based in Seoul, South Korea, is at the forefront of integrating quantum computing with artificial intelligence to revolutionize drug discovery. Using its advanced QUEST-ADMET platform and the Quantum-Dock module, QIC aims to outperform conventional drug development approaches in both accuracy and speed, offering highly precise predictions of drug efficacy and safety.

QIC's global expansion is supported by strategic partnerships, including collaborations with Oxford Quantum Circuits (UK), Quandela (France), and QuEra Computing (US), alongside a joint venture with 48Hour Discovery (Canada). These partnerships enhance QIC's presence in key North American, European and Asian markets. The collaborations are aimed at improving pharmacological predictions, discovering new drug candidates and investigating metalloprotein-ligand interactions and pharmacokinetics. Beyond healthcare, QIC is also exploring quantum computing's potential in the financial sector, aiming to transform algorithmic trading, risk analysis and asset management.

QIC's diverse team of experts in quantum physics, molecular modeling and AI is committed to driving innovations that optimize the drug development process. These efforts have established QIC as a prospective leader in quantum drug discovery, aiming to reduce development costs and timelines while improving drug safety and efficacy. The company's strategy to license out drug candidates developed with its quantum computing technology marks a paradigm shift in the pharmaceutical industry, underscoring Quantum Intelligence's potential for significant growth.

Contact Details

Rainier Communications on behalf of Classiq

Michelle Allard McMahon

[email protected]

Quantum Intelligence Corp. (QIC)

Byung-Hoon Kim, Operations Manager

[email protected]

Company Website

http://www.classiq.io/

View source version on newsdirect.com: https://newsdirect.com/news/classiq-and-quantum-intelligence-corp-qic-korea-partner-on-quantum-accelerated-drug-development-723092450

Classiq Technologies

comtex tracking

COMTEX_450322258/2655/2024-04-04T08:04:49

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Diligent Reader journalist was involved in the writing and production of this article.